Live SpaceX Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Pulmatrix, Inc.

Get SEC filing alerts via email and in your feed for Pulmatrix, Inc.

PULM

Pulmatrix, Inc.

About Pulmatrix, Inc.

Pulmatrix, Inc. is a biopharmaceutical company specializing in inhaled therapies using its proprietary iSPERSE dry powder platform. It develops treatments for respiratory diseases and CNS disorders, including migraine, COPD, and ABPA. The company focuses on innovative drug delivery, aiming to improve efficacy and safety, and seeks strategic partnerships and monetization of its clinical assets in the global respiratory and neurological markets.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Pulmatrix, Inc.

1
1
Pulmatrix, Inc. Pulmatrix Reports Q1 2026 Financial Results, Faces Operational Challenges Amid Merger with Eos

Via official filing (AI summary) | 30 days ago | 0 comments

2
1
Pulmatrix, Inc. Pulmatrix Reports $5.2 Million Net Loss for Fiscal Year 2025, Enters Merger Agreement with Cullgen

Via official filing (AI summary) | 4 months ago | 0 comments

3
1
Pulmatrix, Inc. Pulmatrix Reports No Revenue and Continued Net Loss in Q3 2025

Via official filing (AI summary) | 8 months ago | 0 comments

4
1
Pulmatrix, Inc. Pulmatrix Reports No Revenue and Significant Losses in Latest Financial Filing

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Pulmatrix, Inc. Pulmatrix Reports No Revenue and $1.8 Million Net Loss in Q1 2025 Amid Merger Plans

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Pulmatrix, Inc. Pulmatrix Reports $9.6 Million Net Loss for Fiscal Year 2024, Enters Merger Agreement with Cullgen

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Pulmatrix, Inc. Pulmatrix Reports Decreased Revenue, Improved Losses in Q3 2024, Seeks Additional Funding

Via official filing (AI summary) | over 1 year ago | 0 comments